Clinical trials
HER 2 Negative Breast Cancer clinical trials
Below are recruiting her 2 negative breast cancer clinical trials, each written for real people, not researchers. We’re tracking 913 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07629206Recruiting
Freezing therapy for small, early-stage breast cancer
This study tests whether freezing a small breast tumor (cryoablation) is a safe and effective treatment option for older adults with early-stage, hormone-receptor-positive breast cancer. Instead of surgery, the goal is to destroy the tumor by freezing it in place.
Glendale, CaliforniaAges 70 years+ - NCT06193525RecruitingPhase 2
Talazoparib for advanced breast cancer with a DNA repair defect
This trial tests a drug called talazoparib (a PARP inhibitor) for advanced breast cancer that has a specific DNA repair defect (HRD) or a BRCA mutation. The goal is to see if the drug works better when the patient's tumor is tested for this defect just before treatment.
Leiden, South HollandAges 18 years+ - NCT05879926RecruitingPhase 3
Testing chemo after hormone therapy in premenopausal early breast cancer
This Phase 3 trial checks whether adding chemotherapy after standard hormone-blocking treatment works better for some premenopausal women with early-stage, ER-positive, HER2-negative breast cancer. It targets patients with limited lymph node spread and a lower-to-intermediate tumor “recurrence” risk score.
Birmingham, AlabamaAges 18–60 - NCT06998108RecruitingPhase 3
A new drug with fulvestrant for HR+/HER2- advanced breast cancer
This trial tests a new investigational drug called BEBT-209 combined with fulvestrant (a hormone therapy) versus placebo with fulvestrant for people with a type of breast cancer that is hormone receptor-positive and HER2-negative. It is for those whose cancer has worsened after previous hormone therapy and has spread locally or to other parts of the body.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05800275RecruitingPhase 2
Tucatinib and capecitabine plus spinal trastuzumab for HER2+ cancer
This Phase 2 trial tests a combination of tucatinib and capecitabine (taken by mouth) plus trastuzumab delivered into the spinal fluid, to treat breast cancer that has spread to the leptomeninges (lining around the brain/spinal cord). It may help reduce cancer activity in the spinal fluid and improve symptoms.
BordeauxAges 18 years+ - NCT07574749Recruiting
Breast Cancer Blood Test to Guide Treatment Choices
This study examines tiny particles in your blood from breast cancer cells to better predict which treatments will work best for you. Researchers will collect blood samples and a small tissue sample to understand your cancer's characteristics and help doctors choose more effective therapy.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05939830Recruiting
Skipping axillary lymph node surgery after treatment response
This study looks at whether some breast cancer patients can safely skip a surgery that removes lymph nodes in the armpit after their initial (pre-surgery) treatment shows the armpit is likely clear. It may reduce surgical side effects if the armpit truly responds well.
NanjingAges 18–70 - NCT07182721RecruitingPhase 2
Study of SKB264 plus Inetetamab for advanced HER2+ breast cancer after T-DXd
This trial is testing a combination of two targeted therapies, SKB264 and Inetetamab, for people with advanced HER2-positive breast cancer that has kept growing after treatment with T-DXd and other HER2-targeted therapies. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
ShanghaiAges 18 years+ - NCT06417801Recruiting
Study of ESR1 gene changes in blood in advanced breast cancer
This study looks for changes in the ESR1 gene in the blood of people with advanced HR+/HER2- breast cancer. It compares these blood test results with tumor tissue results to learn more about the cancer.
Salvador, Estado de BahiaAges 18–100 - NCT07037537Recruiting
Nipple-sparing mastectomy with immediate reconstruction (fat and implant)
This trial tests a breast cancer surgery that removes the breast but saves the nipple, followed by immediate reconstruction with an implant and some of your own fat. It's for women with early-stage cancer that hasn't spread to lymph nodes.
Zhengzhou, HenanAges 18–70 - NCT06977893RecruitingPhase 3
Chemo and immunotherapy for HR+ breast cancer before surgery
This trial tests whether adding the immunotherapy drug toripalimab to chemotherapy before surgery helps women with a certain type of breast cancer (HR+, HER2-). It aims to see if this combination works better than chemotherapy alone.
HangzhouAges 18–75 - NCT04065321Recruiting
Blood test for tumor cells in certain early breast cancers
This trial looks at a blood test that may detect “circulating tumor cells” (cancer cells that can travel in the bloodstream) in people with a specific type of breast cancer. It may help doctors better track the disease and guide treatment for people whose tumors have certain hormone and growth-factor features.
Shenyang, LiaoningAges 18–60 - NCT05689619Recruiting
Silibinin after one brain metastasis surgery for lung or breast cancer
This trial studies silibinin, a natural substance, to help prevent brain metastasis from coming back after surgery. It is for people with lung (NSCLC) or breast cancer who have exactly one small brain metastasis that is fully removed and has a specific lab marker in the brain tissue.
GenovaAges 18–70 - NCT06671262RecruitingPhase 2
Immunotherapy plus radiation before breast cancer surgery
This trial tests combining two treatments—an immunotherapy drug (Toripalimab) and radiation—before surgery for a certain type of breast cancer (HR+, HER2-negative) that has spread to lymph nodes. The goal is to see if this combination helps shrink the tumor more than standard therapy alone.
Hangzhou, ZhejiangAges 18–85 - NCT07358377RecruitingPhase 1
Combination therapy for HR-positive, HER2-negative cancer
This trial tests a new drug, HRS-6209, combined with other treatments for people with hormone receptor-positive, HER2-negative cancer. The goal is to see if the combination is safe and works well.
Bowral, New South WalesAges 18 years+ - NCT07156253RecruitingPhase 1
Study of SYN818 with olaparib for advanced solid tumors
This trial is testing a new drug, SYN818, combined with olaparib for people with advanced solid tumors that have certain genetic changes (BRCA mutations or related DNA repair problems). It may be an option if you have ovarian or HER2-negative breast cancer and other treatments are no longer working.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07088263RecruitingPhase 3
Adaptive Chemotherapy for Advanced Breast Cancer
This trial tests a new approach to chemotherapy that adapts over time for people with advanced breast cancer that has not responded to first-line treatment. It is designed to personalize treatment based on how the cancer responds, potentially improving outcomes with fewer side effects.
Guangzhou, GuangdongAges 18–75 - NCT04913064Recruiting
White button mushroom supplement for inflammation in high-risk breast cancer
This trial tests whether a white button mushroom powder supplement can lower inflammation in postmenopausal women who have a high risk of breast cancer. If it helps, it could improve early prevention strategies for people at higher risk.
Duarte, CaliforniaAges 21 years+ - NCT04119024RecruitingPhase 1
Gene-edited immune cells for advanced melanoma or solid tumors
This Phase 1 study tests a gene-modified immune cell treatment for advanced cancers that don’t have standard curative options. It may help by attacking cancer cells that show a specific marker called IL13Rα2 after patients receive “conditioning” chemotherapy to prepare the immune system.
Duarte, CaliforniaAges 18–75 - NCT05472792RecruitingPhase 2
Testing breast radiation after lumpectomy with or without hormone pills
This Phase 2 trial compares different “after-surgery” treatment plans for certain older women with hormone-sensitive early breast cancer. It looks at whether a standard hormone-pills approach or a faster, smaller-area radiation approach (given after lumpectomy) works best to prevent cancer coming back.
Chapel Hill, North CarolinaAges 65 years+ - NCT04282122Recruiting
Personalized radiation plan for older women with early breast cancer
This trial uses individual measures of how sensitive your body’s tissues are to radiation to guide after-surgery breast radiation treatment. It aims to keep treatment safe and effective while tailoring the plan to each person.
Montpellier, OccAges 65 years+ - NCT07084558Recruiting
Testing treatment guided by tumor DNA for hormone positive breast cancer
This trial tests whether using a blood test (circulating tumor DNA) can help guide chemo and hormone therapy for early-stage, hormone receptor positive and HER2 negative breast cancer. The goal is to tailor treatment to your tumor's response, potentially reducing unnecessary side effects.
Vienna, AustriaAges 18–100 - NCT02897700RecruitingPhase 1
Testing chemotherapy choices for early breast cancer after surgery
This Phase 1 study tests different chemotherapy approaches in people with breast cancer that has been surgically removed but is early stage. It aims to find a chemotherapy plan that’s safe and works well right after surgery.
Ganzhou, JiangxiAges 18 years+ - NCT05899387Recruiting
Study fluid after breast surgery
This study looks at a problem called seroma, which is fluid buildup, after certain breast surgeries. It compares different situations where implants or tissue expanders are used, to better understand what to expect and how to manage it.
Augsburg, BavariaAges 18 years+
Hear when a new HER 2 Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for her 2 negative breast cancer?
- Yes. Clin2 currently lists 913 recruiting her 2 negative breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a her 2 negative breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a her 2 negative breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Hormone Receptor Positive HER-2 Negative Breast Cancer
- HR Positive/HER-2 Negative Breast Cancer
- Triple Negative Breast Cancer
- HER2-negative Breast Cancer
- Metastatic Triple-negative Breast Cancer
- Advanced Triple Negative Breast Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.